Similarly, programmed death ligand 1 (PD-L1) upregulation on CD103+ DCs from tumor dLNs impaired cross-presentation, whereas PD-L1 and PD-1 blockade mitigated DC dysfunction (50). This evidence concerns the gene CD274 and neoplasm.